Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Terminated Phase 2 Interventional Results available

A Study to Evaluate U3-1402 in Subjects With Advanced or Metastatic Colorectal Cancer

ClinicalTrials.gov ID: NCT04479436

Public ClinicalTrials.gov record NCT04479436. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced May 6, 2026, 3:21 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Multi-Center, Open-Label, Phase 2 Study to Evaluate Safety and Efficacy of U3-1402 in Subjects With Advanced or Metastatic Colorectal Cancer (CRC)

Study identification

NCT ID
NCT04479436
Recruitment status
Terminated
Study type
Interventional
Phase
Phase 2
Lead sponsor
Daiichi Sankyo
Industry
Enrollment
40 participants

Conditions and interventions

Interventions

  • Patritumab Deruxtecan Drug

Drug

Eligibility (public fields only)

Age range
18 Years to 100 Years
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Sep 13, 2020
Primary completion
Feb 2, 2022
Completion
Feb 2, 2022
Last update posted
May 17, 2025

2020 – 2022

United States locations

U.S. sites
21
U.S. states
18
U.S. cities
20
Facility City State ZIP Site status
Highlands Oncology Fayetteville Arkansas 72703
City of Hope Comprehensive Cancer Center Duarte California 91010
University of Colorado Hospital Aurora Colorado 80045
Moffitt Cancer Center Tampa Florida 33612
Emory University Atlanta Georgia 30322
Northwestern Medical Faculty Foundation NMFF Hematology Oncology Chicago Illinois 60611
John Hopkins Sidney Kimmel Comprehensive Cancer Center Baltimore Maryland 21287
Henry Ford Health System Detroit Michigan 48202
Mayo Clinic Rochester Minnesota 55902
Washington University St Louis Missouri 63110
Nebraska Cancer Specialists Omaha Nebraska 68130
Rutgers Cancer Institute of New Jersey New Brunswick New Jersey 08901
Memorial Sloan Kettering Cancer Center New York New York 10065
Duke University Medical Center Durham North Carolina 27710
West Cancer Center Germantown Tennessee 38138
Sarah Cannon Nashville Tennessee 37203
Mary Crowley Cancer Research Dallas Texas 75230
University of Texas Southwestern Medical Center Dallas Texas 75390
MD Anderson Cancer Center University of Texas Houston Texas 77030
Utah Cancer Specialists Salt Lake City Utah 84106
Virgina Cancer Specialists Fairfax Virginia 22031

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 25 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT04479436, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted May 17, 2025 · Synced May 6, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT04479436 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →